Background and rationale
NAFLD, fibrosis, weight reduction, comorbid metabolic diseases, obese and non-obese, intrahepatic inflammation, hepatic inflammation
NONALCOHOLIC FATTY LIVER DISEASE, FIBROSIS, CHRONIC LIVER DISEASE
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, affecting approximately 25% of the world’s population [Therefore, proper and active management is required to reduce intrahepatic inflammation and fibrosis and to treat comorbid metabolic diseases in patients with NAFLD. However, because effective pharmacological therapies for NAFLD have not yet been approved, non-pharmacologic therapies including weight reduction through dietary control and exercise are the cornerstone treatment for both obese and non-obese NAFLD patients, based on the results of previous studies [Although recent studies have evaluated the association between specific nutrients or dietary habits including low carbohydrate/high-fat diet or intermittent fasting and the development or progression of NAFLD, these studies have been conducted on only a small number of patients, and few have shown significant improvement in hepatic inflammation or fibrosis [